Press Releases

CohBar Announces the Appointment of Dr. John Amatruda to its Board

Menlo Park, California – December 7, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of John M. Amatruda, MD, a CohBar co-founder and scientific advisor, to its board of directors. read-more

CohBar, Inc. Announces Third Quarter 2017 Financial Results

Menlo Park, California – November 13, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) ("CohBar" or the "Company"), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the third quarter ended September 30, 2017. read-more

CohBar Presents Preclinical Data on CB4209/CB4211 Program for NASH at the AASLD Liver Meeting® 2017

Menlo Park, California – October 23, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the presentation of preclinical data on its lead CB4209/CB4211 program for NASH at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place October 20-24, 2017 in Washington DC. NASH (non-alcoholic steatohepatitis) affects as many as 12% of adults in the US and there is currently no approved treatment for the disease. read-more

CohBar Presentation at AASLD Liver Meeting 2017

CB4209 and CB4211 are novel, improved peptide analogs of MOTS-c, a mitochondrially encoded peptide with a potential role in maintaining metabolic homeostasis. Metabolic dysfunction is a common underlying factor in the pathogenesis of many age-related diseases including, non-alcoholic fatty liver disease and steatohepatitis (NAFLD and NASH), obesity, type 2 diabetes, neurodegenerative disease, and cancer. The potential utility of CB4209 and CB4211 for the treatment of NASH, obesity, and type 2 diabetes was evaluated in preclinical models using cultured adipocytes, DIO mice, and the STAM® mouse model of NASH.read-more read-more

CohBar, Inc. Announces Scientific Presentation of CB4209/CB4211 Program for NASH at The AASLD Liver Meeting® 2017

Menlo Park, California – October 4, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) (“CohBar” or the “Company”) today announced that it will present preclinical data on CB4209/CB4211, its lead drug candidate program for nonalcoholic steatohepatitis (NASH) and obesity, at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held October 20-24, 2017, in Washington, D.C. Details of the poster presentation will be announced on October 23rd during the presentation. read-more

CohBar to Present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on September 12, 2017

Menlo Park, California – September 8, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that CohBar’s CEO Simon Allen will be presenting an overview of the Company and its clinical development program at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City on Tuesday, September 12, 2017. read-more

CohBar, Inc. Announces Second Quarter 2017 Financial Results

Menlo Park, California – August 14, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) (“CohBar” or the “Company”), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the second quarter ended June 30, 2017. read-more

CohBar, Inc. Completes US$5.2 Million Private Placement

Menlo Park, California – July 17, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) ("CohBar" or the "Company"), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has closed its previously-announced non-brokered private placement offering (the "Offering"). read-more

CohBar, Inc. Announces Private Placement Offering

Menlo Park, California – June 23, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U) (“CohBar” or the “Company”), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it intends to complete a non-brokered private placement offering (the “Offering”) of up to 3,333,334 units (“Units”) at a price of US$1.50 per unit for gross proceeds of up to US$5,000,000. Each unit will consist of one share of the Company’s common stock and one common stock purchase warrant (each a “Warrant”). Each Warrant will entitle the holder to purchase one share of common stock at a price of US$2.25 per share at any time prior to June 30, 2020. read-more

CohBar, Inc. Announces First Quarter 2017 Financial Results

Menlo Park, California - May 15, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the first quarter ended March 31, 2017. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York

Menlo Park, California – March 30 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York City. read-more

CohBar, Inc. Announces Fourth Quarter 2016 Financial Results

Menlo Park, California – March 22, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the fourth quarter ended December 31, 2016 and provided an update on the Company’s preclinical development program. read-more

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Menlo Park, California – February 21 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to evaluate the potential efficacy of its lead drug candidates, MOTS-c peptide analogs CB4209 and CB4211, in a well-established preclinical model of nonalcoholic steatohepatitis (NASH). With these positive study results, the Company continues to advance its lead drug candidates through IND enabling activities, with plans to initiate human clinical trials in early 2018. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York

Menlo Park, California – February 9, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 2017 BIO CEO & Investor Conference in New York City. read-more

CohBar, Inc.’s CEO Simon Allen to Present at the 9th Annual Biotech Showcase in San Francisco

Menlo Park, California – January 10, 2017 - CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will present at the 9th Annual Biotech Showcase Conference in San Francisco on Wednesday, January 11th, 2017 at 2:30pm Pacific Time. CohBar’s Chief Executive Officer, Simon Allen, will discuss the Company’s recent announcements about its clinical development program and its ongoing discovery of new biologically active peptides in the mitochondrial genome. read-more